Angiotensin-converting enzyme 2 (ACE2) is a human cell surface receptor that has been identified as the main point of entry for SARS-CoV-2 virions, which match and bind ACE2 with their own viral Spike protein S1 subunits. This interaction is therefore a key target in COVID-19 therapeutic research, as its inhibitors may yield a protective effect by preventing SARS-CoV-2 entry into cells. For this reason, protein-protein interaction assays suitable for ACE2-Spike inhibitor screening are relevant to current research.

Formats:

• Our 500 assay point kit allows you to run 500 wells in 384-well format, using a 20 µL reaction volume (5 µL of sample).
• Our 5,000 assay point kit allows you to run 5,000 wells in 384-well format, using a 20 µL reaction volume (5 µL of sample).

Features:

• No-wash steps, no separation steps
• ELISA alternative technology
• Sensitive detection
• Broad sample compatibility
• Small sample volume

The AlphaLISA detection of SARS-CoV-2 S1/ACE2 binding uses acceptor beads coupled to human ACE2 protein and Streptavidin-coated donor beads to capture the biotinylated S1-protein. Donor beads and acceptor beads come into proximity through S1 binding to ACE2. Excitation of the Donor beads provokes the release of singlet oxygen that triggers a cascade of energy transfer reactions in the Acceptor beads, resulting in a sharp emission at 615 nm (Figure 1).This assay can facilitate the screening of inhibitors of S1/ACE2 binding. A competitor of the interaction will disrupt the S1/ACE2 binding leading to a decrease of the AlphaLISA Signal.